PubMed Daily Triage — 2026-08-17
Run timestamp: 2026-08-17T09:00:00Z · Attempt 1 of 3
CRDT window: 2026-08-16 → 2026-08-17
Topics searched: 10 · Unique candidates: 67 · Articles included: 25
Score distribution: 9×1 · 8×1 · 7×3 · 6×10 · 5×4 · 4×4 · 3×2
🔴 HIGH Priority (score ≥ 8)
PMID 42603998 · Score 9 · T3 / T1 · OPEN ACCESS
ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.
Galanina N, Iqbal M, Tomassetti S, … William BM
Blood Neoplasia (ASH) · 2026 Aug · PMC13476554
DOI: 10.1016/j.bneo.2026.100250
Key finding: In the largest real-world lymphoma ctDNA cohort (n=144, Signatera), EOT ctDNA-MRD positivity predicts inferior event-free survival with HR 37.10 (95% CI 6.20–221.8, P<.001), dramatically exceeding PET positivity (HR 5.88). Post-CAR-T ctDNA-MRD negativity predicted prolonged disease-free intervals across B- and T-cell subtypes.
Triage note: Direct clinical-integration signal for MRD-guided lymphoma management. ctDNA outperforms imaging by >6-fold hazard ratio. Immediately actionable for T1/T3 program leads. Open access.
PMID 42604670 · Score 8 · Sentinel · Phase III RCT
Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized phase III clinical trial.
He Q, Li Y, Long J, … Jin F
Radiotherapy and Oncology · 2026 Aug 16
DOI: 10.1016/j.radonc.2026.111746
Key finding: IC-TPF did not improve 3-year PFS vs AC-PF (79% vs 74.5%, P=0.454, n=266, 39-month median follow-up); IC increased hematological toxicity (grade 3-4 leukopenia: 44% vs 22%) while reducing mucosal toxicities during CCRT.
Triage note: Phase III RCT (NCT03574324) providing first-level evidence for NPC chemoradiotherapy sequencing. Important negative result with actionable toxicity trade-off data.
🟡 MEDIUM Priority (score 5–7)
PMID 42604821 · Score 7 · T6 Novel Therapeutics
Emerging therapeutic opportunities targeting nonclassical MHC-I molecules.
Li YR, Chen Y, Yang L · Trends in Molecular Medicine · 2026 Aug 17
DOI: 10.1016/j.molmed.2026.07.012
HLA-E, HLA-F, HLA-G, MR1, and CD1 family as tractable immunotherapy targets for universal off-the-shelf cell therapies. UCLA/Parker Institute review synthesizing structural immunology, single-cell profiling, and early clinical data. High conceptual novelty for next-generation allogeneic immune cell therapies.
PMID 42604608 · Score 7 · T3 / T4 Liquid Biopsy + AI
Proximity-confined DNA walking-nanozyme cascades for multiplexed urinary EV phenotyping and ML-assisted disease stratification.
Lin F, Li W, Hou X, … Dai Y · Biosensors and Bioelectronics · 2026 Aug 13
DOI: 10.1016/j.bios.2026.119109
Proximity-confined nanozyme biosensing platform achieves 91% multiclass diagnostic accuracy (healthy/DM/PCa) from clinical urine samples; ultrasensitive EV phenotyping (CD63/EGFR/PAK6, 10³–10⁴ particles/mL detection limits). Proof-of-concept for non-invasive multi-disease stratification from urine.
PMID 42604595 · Score 7 · T6 Novel Therapeutics
Atezolizumab vs durvalumab for extensive-stage SCLC in Japan: real-world cost and clinical outcomes.
Hirano K et al. · Japanese Journal of Clinical Oncology · 2026 Aug 16
DOI: 10.1093/jjco/hyag128
PSM-matched real-world cohort (n=128, 8 centers): Atezolizumab = similar OS (13.9 vs 14.8 mo, P=0.92) + lower costs (¥1.0M vs ¥1.6M/month, P<.001) + fewer grade≥2 irAEs (11% vs 31%) + dramatically less ILD (3% vs 20%, P=0.004). Clinically actionable for ES-SCLC treatment selection.
PMID 42604060 · Score 6 · T6 / Sentinel
Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.
Wells CR, Pandey A, … Galvani AP · Lancet Regional Health Americas · 2026 Aug 8
DOI: 10.1016/j.lana.2026.101596 · PMC13476578
Yale modeling: mRNA immunotherapies could avert ~49,415 deaths/year and generate $75.55B economic value across NSCLC, pancreatic, renal, and melanoma—exceeding US federal mRNA research funding cuts. Policy-critical analysis; timely given HHS defunding decisions.
PMID 42604808 · Score 6 · T1 Hematologic / T6
Histone deacetylase inhibitors as venetoclax-sensitising partners in acute myeloid leukaemia.
Lee J, Diederich M · British Journal of Pharmacology · 2026 Aug 16
DOI: 10.1111/bph.70641
CACAG-VEN chidamide-based regimen: ORR 76.5–98%, CRi 73.5–93.3%, MRD-negativity 44–61% in older/unfit AML. HDAC1/2/3 mechanistic rationale is strong (MCL-1 suppression); isolated HDAC contribution not yet validated. Biomarker-selected RCTs needed.
PMID 42604150 · Score 6 · T6 Novel Therapeutics
Simultaneous targeting of IL-10 and PD-(L)1 with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses.
Singh L, Zabavnik N, … Helming L · Molecular Therapy Oncology · 2026 Jul 28
DOI: 10.1016/j.omton.2026.201309 · PMC13476703
Merck KGaA/EMD Serono: IL-10 at cancer-serum concentrations suppresses T cells; anti-PD-L1/IL-10-trap bispecific outperforms anti-PD-(L)1 alone for T cell activation and macrophage pro-inflammatory polarization. Preclinical in vitro data; active pharmaceutical pipeline.
PMID 42604014 · Score 6 · T1 Hematologic
The National Childhood Cancer Registry of Chile: a population-based study.
Cerda P et al. · Lancet Regional Health Americas · 2026 Aug 7
DOI: 10.1016/j.lana.2026.101588 · PMC13476546
8821 cases 2007–2023 with 100% national coverage; 5-year survival 71.4% → 80.5%; leukemia dominant (58.6/million), lymphoma 12.7/million. First IARC-validated 100%-coverage LMIC childhood cancer registry — model for global hematologic malignancy surveillance.
PMID 42604807 · Score 6 · Sentinel (First-in-Class Drug Approval)
Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia.
Sun Y, Gao J · Drug Discoveries and Therapeutics · 2026 Aug 14
DOI: 10.5582/ddt.2026.01051
FDA approval July 2026; macrocyclic peptide oral PCSK9 inhibitor; phase III CORALreef: ~60% LDL-C reduction over 52 weeks, placebo-comparable safety. CV outcomes data pending (CORALreef Outcomes trial ongoing). Major drug class event for cardiovascular prevention.
PMID 42604024 · Score 6 · T4 AI/ML Diagnostics
Machine learning to predict adverse perinatal outcomes: a systematic review and meta-analysis.
Zhang J et al. · EClinicalMedicine (Lancet) · 2026 Aug 7
DOI: 10.1016/j.eclinm.2026.104138 · PMC13476551
90 studies; ML AUC 0.73 (PTB), 0.68 (SGA), 0.75 (stillbirth) — moderate performance; ML not better than logistic regression for PTB/SGA (P=0.07/0.31); near-universal high risk of bias. Important calibration signal: ML hype in perinatal prediction not yet substantiated.
PMID 42604142 · Score 6 · T3 Liquid Biopsy
Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision.
Leclerc A, Emery E, Levallet G · Molecular Therapy Oncology · 2026 Jul 28
DOI: 10.1016/j.omton.2026.201308 · PMC13476693
Systematic review: miR-21, miR-10b, miR-182, miR-210 consistently upregulated in GBM; exosomal/CSF composite panels outperform single markers for prognosis and pseudoprogression distinction. miR-1238 as temozolomide-resistance marker. Clinical translation limited by standardization gaps.
PMID 42604637 · Score 6 · T9 Rare Diseases
Lesser-known medication safety considerations in sickle cell disease.
Galadanci N, Kanter J · Expert Opinion on Drug Safety · 2026 Aug 16
DOI: 10.1080/14740338.2026.2719768
UAB Lifespan SCD Center: underrecognized safety risks for SCD-modifying therapies, CV/renal drugs, antibiotics, and corticosteroids in the unique SCD pathophysiology context. Precision-medicine approach essential as new gene therapies and disease-modifying agents enter the SCD pipeline.
PMID 42604458 · Score 6 · T7 Cardiovascular-Metabolic
Estimating GLP-1 Receptor Agonist Eligibility in Australia: Cross-Sectional Analysis of National Health Survey Data.
Castrillon J et al. · Medical Journal of Australia · 2026 Aug
DOI: 10.5694/mja2.70253
39.7% of Australian adults (7.8 million) eligible for GLP-1 RA for chronic weight management; ~339K also qualify under the cardiovascular secondary prevention indication. First population-scale GLP-1 eligibility estimate for Australia; policy-ready reference.
PMID 42604465 · Score 6 · T6 Novel Therapeutics
Predictors of immunotherapy response in gastric cancer: TME and integrative predictive models.
Tsarenkova EA et al. · Clinical and Translational Oncology · 2026 Aug 16
DOI: 10.1007/s12094-026-04547-7
Integrative TME models (immune phenotypes + protein biomarkers + gene signatures + metabolic factors) consistently outperform single biomarkers (PD-L1, MSI, TMB) for gastric cancer immunotherapy response prediction. TME temporal plasticity remains a key barrier to clinical biomarker standardization.
🟢 LOW Priority (score ≤ 5 — included for topic coverage)
| PMID | Score | Topic | Title (brief) |
|---|---|---|---|
| 42604022 | 5 | T1 Hematologic | RUNX1 saRNA + RUNX1-ETO siRNA dual strategy in t(8;21) AML (in vitro) |
| 42604568 | 5 | T1 Hematologic | Palliative care/hospice in r/r DLBCL pre- vs post-CART era (worsening end-of-life patterns) |
| 42604134 | 5 | T6 Therapeutics | GLUT1-targeted STING polyproagonist nanoparticles + anti-PD-L1 combo (preclinical) |
| 42604577 | 5 | Sentinel | H. pylori diagnostic accuracy (serum/urine/stool) meta-analysis, Japan |
| 42603857 | 4 | T7 CV-Metabolic | LCN2 as cardiorenal biomarker in T2DM with CKM syndrome |
| 42604597 | 4 | T8 Aging | Polygenic risk of depression associated with regional brain atrophy in older adults (ADNI) |
| 42604279 | 4 | T7 CV-Metabolic | SGLT2 inhibitors: emerging urological roles (EAU Endourology Section review) |
| 42604028 | 4 | T5 Precision | GPC3-aptamer nanoparticle drug delivery for HCC (preclinical) |
| 42604770 | 3 | T5 Precision | GBM drug therapy review (Japanese language, No Shinkei Geka) |
| 42604792 | 3 | T8 Aging | Multidimensional sleep quality predictors in older adults (cross-national) |
Per-Topic Coverage Summary
| Topic | Candidates | HIGH | Top Score | Notes |
|---|---|---|---|---|
| Hematologic malignancies (T1) | 13 | 1 | 9 (PMID 42603998) | Strong ctDNA-MRD signal; HDAC-VEN in AML |
| CBC / ML hematology (T2) | 1 | 0 | — | Very sparse; widen to 48h window recommended |
| Early cancer detection (T3) | 6 | 1 | 9 (PMID 42603998) | ctDNA-MRD dominates; nanozyme EV platform interesting |
| AI/ML diagnostics (T4) | 15 | 0 | 6 (PMID 42604024) | ML perinatal meta-analysis; important negative calibration |
| Precision oncology (T5) | 12 | 0 | 4 | 8/12 results were Japanese-language reviews; thin window |
| Novel therapeutics (T6) | 15 | 0 | 7 | Strong day for immunotherapy: MHC-I, bispecific, SCLC RWE |
| Cardiovascular-metabolic (T7) | 2 | 0 | 6 | GLP-1 eligibility data; enlicitide FDA approval (sentinel) |
| Aging / longevity (T8) | 4 | 0 | 4 | Thin day; sleep quality + polygenic risk/brain atrophy |
| Rare diseases (T9) | 3 | 0 | 6 | SCD medication safety is clinically important |
| Sentinel | 10 | 1 | 8 (PMID 42604670) | Phase III NPC RCT + enlicitide first oral PCSK9 |
Observations & Alerts
ctDNA-MRD superiority over PET in lymphoma (PMID 42603998, score 9): This study from Natera/OhioHealth in Blood Neoplasia is the clearest clinical-integration signal of the day. EOT ctDNA-MRD HR of 37 vs PET HR of 5.88 argues strongly for ctDNA becoming the preferred MRD modality in lymphoma. Recommend escalation for T1/T3 program review.
Enlicitide FDA approval (PMID 42604807): First oral PCSK9 inhibitor approved — a major drug class event. No CV outcomes data yet but the delivery innovation resolves a key adherence barrier for PCSK9 therapy. Sentinel-level flag for cardiovascular program tracking.
T2 CBC/ML extremely sparse (1 hit): Only 1 article in the 24h window matching CBC + ML. Recommend expanding to 48h or broadening query terms in future runs.
T5 Precision oncology signal low: 8 of 12 results were Japanese-language No Shinkei Geka reviews with English abstracts only. Core precision oncology signal (NGS, somatic mutation, tumor profiling in hematology) was absent today.
mRNA cancer immunotherapy policy signal (PMID 42604060): The Lancet Americas Yale modeling paper is highly timely given US federal mRNA funding cuts. $75.55B value / 49,415 deaths averted projection provides evidence basis for advocacy. Policy-track flag.
Generated by Friday (OpenClaw) · 2026-08-17T09:00:00Z · Attempt 1